Viral Vectors and Plasmid DNA Market Report 2026

The viral vectors and plasmid dna market size has grown strongly in recent years. It will grow from $1.38 billion in 2025 to $1.47 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to limited availability of viral vectors, reliance on research-grade plasmid dna, increasing gene therapy pipelines, growing biopharmaceutical r&d activities, adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to development of clinical-grade and gmp plasmid dna, expansion of viral vector applications in cancer and infectious diseases, rising investment in gene therapy, growing demand for immunotherapy solutions, adoption of novel vector platforms such as aav and lentiviral vectors. Major trends in the forecast period include rising adoption of plasmid dna and viral vectors in gene therapy, expansion of viral vector platforms for cancer and genetic disorder treatments, growth in gmp-grade plasmid dna production for clinical applications, increasing research on novel adeno-associated and lentiviral vectors, integration of plasmid dna and viral vectors in immunotherapy and vaccine development.

The rising incidence of tuberculosis is expected to drive the expansion of the viral vector and plasmid DNA market in the coming years. Tuberculosis (TB) is a contagious and potentially serious infectious disease caused by bacterial infection, primarily affecting the lungs, although it can also spread to other parts of the body. Plasmid DNA vaccines have been utilized to deliver genes that encode microbial antigens for tuberculosis. These vaccines can be engineered to express specific antigens of Mycobacterium tuberculosis, the bacterium responsible for TB, and are typically administered via intramuscular injection. For example, in February 2024, according to GOV.UK, a UK-based government department, tuberculosis cases in England rose by 10.7% in 2023, increasing from 4,380 cases in 2022 to 4,850 cases. As a result, the growing prevalence of tuberculosis is contributing to the growth of the viral vector and plasmid DNA market.

Leading companies operating in the viral vector and plasmid DNA market are increasingly focused on launching innovative products, such as helper plasmids, to strengthen their competitive position. Helper plasmids are a type of plasmid DNA used in the production of viral vectors, including adeno-associated viral vectors (AAV), which are widely employed in gene therapy applications. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced the off-the-shelf pHelper plasmid. This helper plasmid is designed to accelerate progress from early discovery to commercial manufacturing of AAV-based gene therapy programs while ensuring supply reliability. As part of a comprehensive portfolio of contract development and manufacturing organization (CDMO) products and services, helper plasmids support viral vector packaging in cell and gene therapy workflows and help simplify complex supply chains. Adeno-associated viral vectors, commonly used in gene therapy, are produced using helper plasmids.

In January 2023, Moderna Inc., a US-based pharmaceutical and biotechnology company, acquired OriCiro Genomics for $85 million. This acquisition is intended to accelerate Moderna’s pipeline development by enhancing its capabilities in plasmid DNA synthesis and amplification, which are essential components in the production of messenger RNA (mRNA). OriCiro Genomics is a Japan-based genome technology company that specializes in the development and commercialization of cell-free systems for the assembly and amplification of circular DNA molecules, including plasmids and viral vectors.

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Каnеkа Соrроrаtіоn, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene.

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vectors and plasmid dna market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the viral vectors and plasmid DNA market by increasing costs of imported raw materials, bioreactors, and specialized lab equipment used in plasmid and viral vector production. Segments like GMP-grade plasmid DNA and adenoviral or lentiviral vectors are most affected, particularly in North America and Europe where imports are high. This has resulted in higher production costs and potential delays in research and clinical applications. On the positive side, tariffs have encouraged domestic manufacturing, investment in local production facilities, and innovation in cost-effective vector technologies.

The viral vectors and plasmid dna market research report is one of a series of new reports that provides viral vectors and plasmid dna market statistics, including viral vectors and plasmid dna industry global market size, regional shares, competitors with a viral vectors and plasmid dna market share, detailed viral vectors and plasmid dna market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors and plasmid dna industry. This viral vectors and plasmid dna market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vectors are tools derived from viral genomes that have been transformed into plasmid-based technologies and modified for safety by removing several essential genes, with viral components separated in the process. In contrast, plasmid DNA refers to small, circular DNA molecules found in certain bacteria and other microorganisms. These molecules are physically separate from chromosomal DNA and are capable of independent replication.

The primary product types in viral vectors and plasmid DNA include plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that exists independently of a cell’s chromosomal DNA and occurs naturally in bacterial cells as well as in some eukaryotes. Plasmid genes often provide genetic advantages to bacteria, such as antibiotic resistance. These technologies are applied in the treatment of infectious diseases, genetic disorders, cancer, and other conditions, and are used in gene and cancer therapies, viral infection treatments, immunotherapy, formulation development, and additional applications. The key end-use sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies.

The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.